Akti-1/2
别名: Akt Inhibitor VIII
Akti-1/2 (Akt Inhibitor VIII)是高度选择性的Akt1/Akt2抑制剂，IC50分别为58 nM/210 nM，对Akt1的选择性比对Akt3高36倍。Akti-1/2 可诱导凋亡。
Akti-1/2 Chemical Structure
CAS: 612847-09-3
产品质控
批次：
纯度：
99.11%
99.11
Akti-1/2相关产品
相关信号通路图
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| ME-180 cell | Growth inhibition assay | Inhibition of human ME-180 cell growth in a cell viability assay, IC50=3.15011 Μm | SANGER | ||
| NCI-H526 cells | Growth inhibition assay | Inhibition of Akt-mediated antiapoptotic activity in human NCI-H526 cells assessed as disruption of protein-Apaf-1 complex at 50 uM after 24 hrs by Western blot analysis | 17603540 | ||
| MDA-MB-415 cell | Growth inhibition assay | Inhibition of human MDA-MB-415 cell growth in a cell viability assay, IC50=1.73449 μM | SANGER | ||
| MDA-MB-468 cell | Growth inhibition assay | Inhibition of human MDA-MB-468 cell growth in a cell viability assay, IC50=3.70773 μM | SANGER | ||
| IGROV-1 cell | Growth inhibition assay | Inhibition of human IGROV-1 cell growth in a cell viability assay, IC50=0.72328 Μm | SANGER | ||
| MDA-MB-361 cell | Growth inhibition assay | Inhibition of human MDA-MB-361 cell growth in a cell viability assay, IC50=0.48995 μM | SANGER | ||
| HCC70 cell | Growth inhibition assay | Inhibition of human HCC70 cell growth in a cell viability assay, IC50=0.75078 μM | SANGER | ||
| HGC-27 cell | Growth inhibition assay | Inhibition of human HGC-27 cell growth in a cell viability assay, IC50=0.15033 μM | SANGER | ||
| ETK-1 | Growth inhibition assay | Inhibition of human ETK-1 cell growth in a cell viability assay, IC50=4.57383 μM | SANGER | ||
| EFM-19 cell | Growth inhibition assay | Inhibition of human EFM-19 cell growth in a cell viability assay, IC50=0.56408 μM | SANGER | ||
| EFO-21 cell | Growth inhibition assay | Inhibition of human EFO-21 cell growth in a cell viability assay, IC50=4.43468 μM | SANGER | ||
| ECC12 cell | Growth inhibition assay | Inhibition of human ECC12 cell growth in a cell viability assay, IC50=8.88569 μM | SANGER | ||
| DSH1 cell | Growth inhibition assay | Inhibition of human DSH1 cell growth in a cell viability assay, IC50=0.98722 μM | SANGER | ||
| DOK cell | Growth inhibition assay | Inhibition of human DOK cell growth in a cell viability assay, IC50=4.15134 μM | SANGER | ||
| DMS-273 cell | Growth inhibition assay | Inhibition of human DMS-273 cell growth in a cell viability assay, IC50=4.15134 μM | SANGER | ||
| Calu-3 cell | Growth inhibition assay | Inhibition of human Calu-3 cell growth in a cell viability assay, IC50=3.65321 μM | SANGER | ||
| Calu-1 cell | Growth inhibition assay | Inhibition of human Calu-1 cell growth in a cell viability assay, IC50=7.25613 μM | SANGER | ||
| Ca9-22 cell | Growth inhibition assay | Inhibition of human Ca9-22 cell growth in a cell viability assay, IC50=5.97333 μM | SANGER | ||
| Ca-Ski cell | Growth inhibition assay | Inhibition of human Ca-Ski cell growth in a cell viability assay, IC50=5.3411 μM | SANGER | ||
| CTB-1 cell | Growth inhibition assay | Inhibition of human CTB-1 cell growth in a cell viability assay, IC50=7.59751 μM | SANGER | ||
| COR-L279 cell | Growth inhibition assay | Inhibition of human COR-L279 cell growth in a cell viability assay, IC50=1.68064 μM | SANGER | ||
| COLO-205 cell | Growth inhibition assay | Inhibition of human COLO-205 cell growth in a cell viability assay, IC50=1.99706 μM | SANGER | ||
| CHP-212 cell | Growth inhibition assay | Inhibition of human CHP-212 cell growth in a cell viability assay, IC50=4.55867 μM | SANGER | ||
| CESS cell | Growth inhibition assay | Inhibition of human CESS cell growth in a cell viability assay, IC50=2.70089 μM | SANGER | ||
| CCRF-CEM cell | Growth inhibition assay | Inhibition of human CCRF-CEM cell growth in a cell viability assay, IC50=4.93541 μM | SANGER | ||
| CCF-STTG1 cell | Growth inhibition assay | Inhibition of human CCF-STTG1 cell growth in a cell viability assay, IC50=6.81501 μM | SANGER | ||
| YKG-1 cell | Growth inhibition assay | Inhibition of human YKG-1 cell growth in a cell viability assay, IC50=1.01806 μM | SANGER | ||
| VMRC-RCZ cell | Growth inhibition assay | Inhibition of human VMRC-RCZ cell growth in a cell viability assay, IC50=3.70955 μM | SANGER | ||
| UACC-893 cell | Growth inhibition assay | Inhibition of human UACC-893 cell growth in a cell viability assay, IC50=5.29339 μM | SANGER | ||
| UACC-62 cell | Growth inhibition assay | Inhibition of human UACC-62 cell growth in a cell viability assay, IC50=27.0545 μM | SANGER | ||
| U251 cell | Growth inhibition assay | Inhibition of human U251 cell growth in a cell viability assay, IC50=19.204 μM | SANGER | ||
| U-698-M cell | Growth inhibition assay | Inhibition of human U-698-M cell growth in a cell viability assay, IC50=39.0015 μM | SANGER | ||
| U-118-MG cell | Growth inhibition assay | Inhibition of human U-118-MG cell growth in a cell viability assay, IC50=9.90258 μM | SANGER | ||
| TT cell | Growth inhibition assay | Inhibition of human TT cell growth in a cell viability assay, IC50=5.32724 μM | SANGER | ||
| TE-8 cell | Growth inhibition assay | Inhibition of human TE-8 cell growth in a cell viability assay, IC50=24.5243 μM | SANGER | ||
| TE-5 cell | Growth inhibition assay | Inhibition of human TE-5 cell growth in a cell viability assay, IC50=4.82452 μM | SANGER | ||
| TE-15 cell | Growth inhibition assay | Inhibition of human TE-15 cell growth in a cell viability assay, IC50=6.49393 μM | SANGER | ||
| TE-10 cell | Growth inhibition assay | Inhibition of human TE-10 cell growth in a cell viability assay, IC50=9.04225 μM | SANGER | ||
| CAL-85-1 cell | Growth inhibition assay | Inhibition of human CAL-85-1 cell growth in a cell viability assay, IC50=5.95309 μM | SANGER | ||
| CAL-54 cell | Growth inhibition assay | Inhibition of human CAL-54 cell growth in a cell viability assay, IC50=4.88625 μM | SANGER | ||
| CAL-51 cell | Growth inhibition assay | Inhibition of human CAL-51 cell growth in a cell viability assay, IC50=7.62841 Μm | SANGER | ||
| CAL-33 cell | Growth inhibition assay | Inhibition of human CAL-33 cell growth in a cell viability assay, IC50=3.43125 μM | SANGER | ||
| C3A cell | Growth inhibition assay | Inhibition of human C3A cell growth in a cell viability assay, IC50=4.42192 μM | SANGER | ||
| C2BBe1 cell | Growth inhibition assay | Inhibition of human C2BBe1 cell growth in a cell viability assay, IC50=13.6679 μM | SANGER | ||
| C-33-A cell | Growth inhibition assay | Inhibition of human C-33-A cell growth in a cell viability assay, IC50=12.4783 μM | SANGER | ||
| BxPC-3 cell | Growth inhibition assay | Inhibition of human BxPC-3 cell growth in a cell viability assay, IC50=2.22442 μM | SANGER | ||
| BB30-HNC cell | Growth inhibition assay | Inhibition of human BB30-HNC cell growth in a cell viability assay, IC50=2.86449 μM | SANGER | ||
| AU565 cell | Growth inhibition assay | Inhibition of human AU565 cell growth in a cell viability assay, IC50=1.23917 μM | SANGER | ||
| AN3-CA cell | Growth inhibition assay | Inhibition of human AN3-CA cell growth in a cell viability assay, IC50=1.65611 μM | SANGER | ||
| A498 cell | Growth inhibition assay | Inhibition of human A498 cell growth in a cell viability assay, IC50=1.08134 μM | SANGER | ||
| A427 cell | Growth inhibition assay | Inhibition of human A427 cell growth in a cell viability assay, IC50=3.07693 μM | SANGER | ||
| A4-Fuk cell | Growth inhibition assay | Inhibition of human A4-Fuk cell growth in a cell viability assay, IC50=1.8583 μM | SANGER | ||
| 8-MG-BA cell | Growth inhibition assay | Inhibition of human 8-MG-BA cell growth in a cell viability assay, IC50=8.63401 μM | SANGER | ||
| 769-P cell | Growth inhibition assay | Inhibition of human 769-P cell growth in a cell viability assay, IC50=1.10483 μM | SANGER | ||
| 697 cell | Growth inhibition assay | Inhibition of human 697 cell growth in a cell viability assay, IC50=7.17746 μM | SANGER | ||
| 639-V cell | Growth inhibition assay | Inhibition of human 639-V cell growth in a cell viability assay, IC50=5.8773 μM | SANGER | ||
| 23132-87 cell | Growth inhibition assay | Inhibition of human 23132-87 cell growth in a cell viability assay, IC50=0.75938 μM | SANGER | ||
| 22RV1 cell | Growth inhibition assay | Inhibition of human 22RV1 cell growth in a cell viability assay, IC50=6.61424 μM | SANGER | ||
| T47D cell | Growth inhibition assay | Inhibition of human T47D cell growth in a cell viability assay, IC50=0.5162 μM | SANGER | ||
| SW954 cell | Growth inhibition assay | Inhibition of human SW954 cell growth in a cell viability assay, IC50=5.85783 μM | SANGER | ||
| SW872 cell | Growth inhibition assay | Inhibition of human SW872 cell growth in a cell viability assay, IC50=14.1435 μM | SANGER | ||
| SW780 cell | Growth inhibition assay | Inhibition of human SW780 cell growth in a cell viability assay, IC50=4.89358 μM | SANGER | ||
| SW1710 cell | Growth inhibition assay | Inhibition of human SW1710 cell growth in a cell viability assay, IC50=1.38892 μM | SANGER | ||
| SU-DHL-1 cell | Growth inhibition assay | Inhibition of human SU-DHL-1 cell growth in a cell viability assay, IC50=6.81543 μM | SANGER | ||
| SR cell | Growth inhibition assay | Inhibition of human SR cell growth in a cell viability assay, IC50=13.0746 μM | SANGER | ||
| SNU-C2B cell | Growth inhibition assay | Inhibition of human SNU-C2B cell growth in a cell viability assay, IC50=22.2673 μM | SANGER | ||
| SNU-C1 cell | Growth inhibition assay | Inhibition of human SNU-C1 cell growth in a cell viability assay, IC50=2.00948 μM | SANGER | ||
| SNU-423 cell | Growth inhibition assay | Inhibition of human SNU-423 cell growth in a cell viability assay, IC50=5.94933 μM | SANGER | ||
| SNU-387 cell | Growth inhibition assay | Inhibition of human SNU-387 cell growth in a cell viability assay, IC50=4.19544 μM | SANGER | ||
| SNB75 cell | Growth inhibition assay | Inhibition of human SNB75 cell growth in a cell viability assay, IC50=7.8297 μM | SANGER | ||
| human SN12C cell | Growth inhibition assay | Inhibition of human SN12C cell growth in a cell viability assay, IC50=17.1967 μM | SANGER | ||
| SK-MES-1 cell | Growth inhibition assay | Inhibition of human SK-MES-1 cell growth in a cell viability assay, IC50=2.10096 μM | SANGER | ||
| SK-MEL-3 cell | Growth inhibition assay | Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50=21.4696 μM | SANGER | ||
| SK-MEL-24 cell | Growth inhibition assay | Inhibition of human SK-MEL-24 cell growth in a cell viability assay, IC50=13.1675 μM | SANGER | ||
| SK-LU-1 cell | Growth inhibition assay | Inhibition of human SK-LU-1 cell growth in a cell viability assay, IC50=42.043 μM | SANGER | ||
| SK-LMS-1 cell | Growth inhibition assay | Inhibition of human SK-LMS-1 cell growth in a cell viability assay, IC50=8.76452 μM | SANGER | ||
| SK-CO-1 cell | Growth inhibition assay | Inhibition of human SK-CO-1 cell growth in a cell viability assay, IC50=10.6394 μM | SANGER | ||
| SJSA-1 cell | Growth inhibition assay | Inhibition of human SJSA-1 cell growth in a cell viability assay, IC50=36.9072 μM | SANGER | ||
| SIG-M5 cell | Growth inhibition assay | Inhibition of human SIG-M5 cell growth in a cell viability assay, IC50=12.6604 μM | SANGER | ||
| SF295 cell | Growth inhibition assay | Inhibition of human SF295 cell growth in a cell viability assay, IC50=13.6183 μM | SANGER | ||
| SF268 cell | Growth inhibition assay | Inhibition of human SF268 cell growth in a cell viability assay, IC50=15.1387 μM | SANGER | ||
| SF126 cell | Growth inhibition assay | Inhibition of human SF126 cell growth in a cell viability assay, IC50=10.6746 μM | SANGER | ||
| SCC-9 cell | Growth inhibition assay | Inhibition of human SCC-9 cell growth in a cell viability assay, IC50=3.08536 μM | SANGER | ||
| SCC-4 cell | Growth inhibition assay | Inhibition of human SCC-4 cell growth in a cell viability assay, IC50=9.59283 μM | SANGER | ||
| SCC-25 cell | Growth inhibition assay | Inhibition of human SCC-25 cell growth in a cell viability assay, IC50=15.8179 μM | SANGER | ||
| SBC-5 cell | Growth inhibition assay | Inhibition of human SBC-5 cell growth in a cell viability assay, IC50=20.8325 μM | SANGER | ||
| RXF393 cell | Growth inhibition assay | Inhibition of human RXF393 cell growth in a cell viability assay, IC50=20.5863 μM | SANGER | ||
| RVH-421 cell | Growth inhibition assay | Inhibition of human RVH-421 cell growth in a cell viability assay, IC50=32.3606 μM | SANGER | ||
| RT-112 cell | Growth inhibition assay | Inhibition of human RT-112 cell growth in a cell viability assay, IC50=6.71952 μM | SANGER | ||
| RS4-11 cell | Growth inhibition assay | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50=6.68645 μM | SANGER | ||
| RPMI-8402 cell | Growth inhibition assay | Inhibition of human RPMI-8402 cell growth in a cell viability assay, IC50=16.343 μM | SANGER | ||
| RPMI-2650 cell | Growth inhibition assay | Inhibition of human RPMI-2650 cell growth in a cell viability assay, IC50=5.77947 μM | SANGER | ||
| RO82-W-1 cell | Growth inhibition assay | Inhibition of human RO82-W-1 cell growth in a cell viability assay, IC50=47.2783 μM | SANGER | ||
| RKO cell | Growth inhibition assay | Inhibition of human RKO cell growth in a cell viability assay, IC50=19.4439 μM | SANGER | ||
| RERF-LC-MS cell | Growth inhibition assay | Inhibition of human RERF-LC-MS cell growth in a cell viability assay, IC50=26.1347 μM | SANGER | ||
| REH cell | Growth inhibition assay | Inhibition of human REH cell growth in a cell viability assay, IC50=11.4883 μM | SANGER | ||
| RD cell | Growth inhibition assay | Inhibition of human RD cell growth in a cell viability assay, IC50=20.6036 μM | SANGER | ||
| RCC10RGB cell | Growth inhibition assay | Inhibition of human RCC10RGB cell growth in a cell viability assay, IC50=8.6567 μM | SANGER | ||
| PF-382 cell | Growth inhibition assay | Inhibition of human PF-382 cell growth in a cell viability assay, IC50=11.6828 μM | SANGER | ||
| PC-3 cell | Growth inhibition assay | Inhibition of human PC-3 cell growth in a cell viability assay, IC50=10.5135 μM | SANGER | ||
| PANC-10-05 cell | Growth inhibition assay | Inhibition of human PANC-10-05 cell growth in a cell viability assay, IC50=14.9959 μM | SANGER | ||
| PANC-03-27 cell | Growth inhibition assay | Inhibition of human PANC-03-27 cell growth in a cell viability assay, IC50=8.71082 μM | SANGER | ||
| PA-1 cell | Growth inhibition assay | Inhibition of human PA-1 cell growth in a cell viability assay, IC50=9.07615 μM | SANGER | ||
| P30-OHK cell | Growth inhibition assay | Inhibition of human P30-OHK cell growth in a cell viability assay, IC50=4.536 μM | SANGER | ||
| P12-ICHIKAWA cell | Growth inhibition assay | Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay, IC50=14.7683 μM | SANGER | ||
| OVCAR-4 cell | Growth inhibition assay | Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50=30.466 μM | SANGER | ||
| OVCAR-3 cell | Growth inhibition assay | Inhibition of human OVCAR-3 cell growth in a cell viability assay, IC50=1.84415 μM | SANGER | ||
| OS-RC-2 cell | Growth inhibition assay | Inhibition of human OS-RC-2 cell growth in a cell viability assay, IC50=8.52307 μM | SANGER | ||
| OMC-1 cell | Growth inhibition assay | Inhibition of human OMC-1 cell growth in a cell viability assay, IC50=9.25098 μM | SANGER | ||
| OE33 cell | Growth inhibition assay | Inhibition of human OE33 cell growth in a cell viability assay, IC50=1.88926 μM | SANGER | ||
| OE19 cell | Growth inhibition assay | Inhibition of human OE19 cell growth in a cell viability assay, IC50=7.76684 μM | SANGER | ||
| OCUB-M cell | Growth inhibition assay | Inhibition of human OCUB-M cell growth in a cell viability assay, IC50=7.72152 μM | SANGER | ||
| OCI-AML2 cell | Growth inhibition assay | Inhibition of human OCI-AML2 cell growth in a cell viability assay, IC50=33.2531 μM | SANGER | ||
| OAW-42 cell | Growth inhibition assay | Inhibition of human OAW-42 cell growth in a cell viability assay, IC50=7.31565 μM | SANGER | ||
| NY cell | Growth inhibition assay | Inhibition of human NY cell growth in a cell viability assay, IC50=31.1864 μM | SANGER | ||
| NUGC-3 cell | Growth inhibition assay | Inhibition of human NUGC-3 cell growth in a cell viability assay, IC50=16.5906 μM | SANGER | ||
| NOS-1 cell | Growth inhibition assay | Inhibition of human NOS-1 cell growth in a cell viability assay, IC50=1.36953 μM | SANGER | ||
| NMC-G1 cell | Growth inhibition assay | Inhibition of human NMC-G1 cell growth in a cell viability assay, IC50=42.6693 μM | SANGER | ||
| NKM-1 cell | Growth inhibition assay | Inhibition of human NKM-1 cell growth in a cell viability assay, IC50=2.75923 μM | SANGER | ||
| NH-12 cell | Growth inhibition assay | Inhibition of human NH-12 cell growth in a cell viability assay, IC50=0.60864 μM | SANGER | ||
| NCI-N87 cell | Growth inhibition assay | Inhibition of human NCI-N87 cell growth in a cell viability assay, IC50=29.3042 μM | SANGER | ||
| NCI-H838 cell | Growth inhibition assay | Inhibition of human NCI-H838 cell growth in a cell viability assay, IC50=31.4118 μM | SANGER | ||
| NCI-H747 cell | Growth inhibition assay | Inhibition of human NCI-H747 cell growth in a cell viability assay, IC50=7.62799 μM | SANGER | ||
| NCI-H661 cell | Growth inhibition assay | Inhibition of human NCI-H661 cell growth in a cell viability assay, IC50=5.42326 μM | SANGER | ||
| NCI-H650 cell | Growth inhibition assay | Inhibition of human NCI-H650 cell growth in a cell viability assay, IC50=7.59877 μM | SANGER | ||
| NCI-H64 cell | Growth inhibition assay | Inhibition of human NCI-H64 cell growth in a cell viability assay, IC50=12.5431 μM | SANGER | ||
| NCI-H630 cell | Growth inhibition assay | Inhibition of human NCI-H630 cell growth in a cell viability assay, IC50=5.51055 μM | SANGER | ||
| NCI-H596 | Growth inhibition assay | Inhibition of human NCI-H596 cell growth in a cell viability assay, IC50=17.5708 μM | SANGER | ||
| NCI-H526 cell | Growth inhibition assay | Inhibition of human NCI-H526 cell growth in a cell viability assay, IC50=22.8873μM | SANGER | ||
| NCI-H522 cell | Growth inhibition assay | Inhibition of human NCI-H522 cell growth in a cell viability assay, IC50=11.0874 μM | SANGER | ||
| NCI-H520 cell | Growth inhibition assay | Inhibition of human NCI-H520 cell growth in a cell viability assay, IC50=1.13303 μM | SANGER | ||
| NCI-H460 cell | Growth inhibition assay | Inhibition of human NCI-H460 cell growth in a cell viability assay, IC50=4.62993 μM | SANGER | ||
| NCI-H358 cell | Growth inhibition assay | Inhibition of human NCI-H358 cell growth in a cell viability assay, IC50=19.7233 μM | SANGER | ||
| NCI-H345 cell | Growth inhibition assay | Inhibition of human NCI-H345 cell growth in a cell viability assay, IC50=16.2706 μM | SANGER | ||
| NCI-H292 cell | Growth inhibition assay | Inhibition of human NCI-H292 cell growth in a cell viability assay, IC50=6.04837 μM | SANGER | ||
| NCI-H2452 cell | Growth inhibition assay | Inhibition of human NCI-H2452 cell growth in a cell viability assay, IC50=26.6594 μM | SANGER | ||
| NCI-H2405 cell | Growth inhibition assay | Inhibition of human NCI-H2405 cell growth in a cell viability assay, IC50=10.4212 μM | SANGER | ||
| NCI-H2347 cell | Growth inhibition assay | Inhibition of human NCI-H2347 cell growth in a cell viability assay, IC50=16.1581 μM | SANGER | ||
| NCI-H2342 cell | Growth inhibition assay | Inhibition of human NCI-H2342 cell growth in a cell viability assay, IC50=0.93779 μM | SANGER | ||
| NCI-H2228 cell | Growth inhibition assay | Inhibition of human NCI-H2228 cell growth in a cell viability assay, IC50=2.28604 μM | SANGER | ||
| NCI-H2196 cell | Growth inhibition assay | Inhibition of human NCI-H2196 cell growth in a cell viability assay, IC50=24.8003 μM | SANGER | ||
| NCI-H2170 cell | Growth inhibition assay | Inhibition of human NCI-H2170 cell growth in a cell viability assay, IC50=18.1028 μM | SANGER | ||
| NCI-H2126 cell | Growth inhibition assay | Inhibition of human NCI-H2126 cell growth in a cell viability assay, IC50=12.3371 μM | SANGER | ||
| NCI-H2122 cell | Growth inhibition assay | Inhibition of human NCI-H2122 cell growth in a cell viability assay, IC50=10.1385 μM | SANGER | ||
| NCI-H2030 cell | Growth inhibition assay | Inhibition of human NCI-H2030 cell growth in a cell viability assay, IC50=1.94483 μM | SANGER | ||
| NCI-H2009 cell | Growth inhibition assay | Inhibition of human NCI-H2009 cell growth in a cell viability assay, IC50=7.39019 μM | SANGER | ||
| NCI-H1993 cell | Growth inhibition assay | Inhibition of human NCI-H1993 cell growth in a cell viability assay, IC50=22.615 μM | SANGER | ||
| NCI-H1963 cell | Growth inhibition assay | Inhibition of human NCI-H1963 cell growth in a cell viability assay, IC50=19.7494 μM | SANGER | ||
| NCI-H1792 cell | Growth inhibition assay | Inhibition of human NCI-H1792 cell growth in a cell viability assay, IC50=29.8379 μM | SANGER | ||
| NCI-H1770 cell | Growth inhibition assay | Inhibition of human NCI-H1770 cell growth in a cell viability assay, IC50=34.1793 μM | SANGER | ||
| NCI-H1755 cell | Growth inhibition assay | Inhibition of human NCI-H1755 cell growth in a cell viability assay, IC50=1.05531 μM | SANGER | ||
| NCI-H1734 cell | Growth inhibition assay | Inhibition of human NCI-H1734 cell growth in a cell viability assay, IC50=10.7788 μM | SANGER | ||
| NCI-H1703 cell | Growth inhibition assay | Inhibition of human NCI-H1703 cell growth in a cell viability assay, IC50=15.577 μM | SANGER | ||
| NCI-H1651 cell | Growth inhibition assay | Inhibition of human NCI-H1651 cell growth in a cell viability assay, IC50=16.4338 μM | SANGER | ||
| NCI-H1650 cell | Growth inhibition assay | Inhibition of human NCI-H1650 cell growth in a cell viability assay, IC50=11.5134 μM | SANGER | ||
| NCI-H1648 cell | Growth inhibition assay | Inhibition of human NCI-H1648 cell growth in a cell viability assay, IC50=5.7551 μM | SANGER | ||
| NCI-H1623 cell | Growth inhibition assay | Inhibition of human NCI-H1623 cell growth in a cell viability assay, IC50=15.0596 μM | SANGER | ||
| NCI-H1618 cel | Growth inhibition assay | Inhibition of human NCI-H1618 cell growth in a cell viability assay, IC50=21.9982 μM | SANGER | ||
| ES7 cell | Growth inhibition assay | Inhibition of human ES7 cell growth in a cell viability assay, IC50=1.34511 μM | SANGER | ||
| EW-3 cell | Growth inhibition assay | Inhibition of human EW-3 cell growth in a cell viability assay, IC50=5.64414 μM | SANGER | ||
| EB2 cell | Growth inhibition assay | Inhibition of human EB2 cell growth in a cell viability assay, IC50=7.75468 μM | SANGER | ||
| DoTc2-4510 cell | Growth inhibition assay | Inhibition of human DoTc2-4510 cell growth in a cell viability assay, IC50=3.43202 μM | SANGER | ||
| Detroit562 cell | Growth inhibition assay | Inhibition of human Detroit562 cell growth in a cell viability assay, IC50=4.79465 μM | SANGER | ||
| DV-90 cell | Growth inhibition assay | Inhibition of human DV-90 cell growth in a cell viability assay, IC50=6.03122 μM | SANGER | ||
| NCI-H1563 cell | Growth inhibition assay | Inhibition of human NCI-H1563 cell growth in a cell viability assay, IC50=0.54246 μM | SANGER | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | Akti-1/2 (Akt Inhibitor VIII)是高度选择性的Akt1/Akt2抑制剂，IC50分别为58 nM/210 nM，对Akt1的选择性比对Akt3高36倍。Akti-1/2 可诱导凋亡。 | ||||||
|---|---|---|---|---|---|---|---|
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | 在基于细胞的IPKA (C33A)试验中，Akti-1/2抑制Akt1和Akt2，IC50分别为305 nM和2086 nM。在HT29，MCF7，和A2780细胞中，Akti-1/2通过急剧增加caspase-3活性诱导细胞凋亡。[1] 在肝细胞中，Akti-1/2阻断胰岛素调节PEPCK，G6Pase表达，和FOXO1活性。[2] Akti-1/2也会通过阻断PKB强烈增强PAR-1-介导的血小板聚集。[3] 在HCC827，NCI-H522，NCI-1651，和PC-9细胞中，Akti-1/2抑制细胞生长，IC50 为4.7 μM，7.25 μM，和9.5 μM，结合时，Akti-1/2会增强细胞生长和凋亡的抑制。[4] |
|||
|---|---|---|---|---|
| 激酶实验 | 激酶筛选 | |||
| 简而言之，所有试验(25.5 μl在21°C下进行30 min)使用Biomek 2000实验室自动化工作站在96孔格式中进行。反应包含5–20 mU纯化的激酶和底物肽或蛋白质，通过加入10 mM 乙酸镁和5，20，或50 μM ATP ([γ-33P]-ATP, 800 cpm/pmol)起始。 | ||||
| 细胞实验 | 细胞系 | HCC827，NCI-H522，NCI-1651，和 PC-9 细胞 | ||
| 浓度 | ~10 μM | |||
| 孵育时间 | 96小时 | |||
| 方法 | AKTi-1/2的细胞生长抑制作用使用96小时磺酰罗丹明B试验(SRB)研究。每个化合物抑制50%细胞生长的浓度(IC50)在GraphPad Prism 6.0中使用非线性回归分析和S形剂量-反应(可变斜率)方程计算。 |
|||
| 实验图片 | 检测方法 | 检测指标 | 实验图片 | PMID |
| Western blot | p-AKT / AKT / p-Foxo3a / p-GSK3β / p-p70S6K / p-S6 / p-4EBP1 / Cyclin D1 / Cyclin D2 / Cyclin D3 / p-Rb / p27 |
|
18725974 | |
| Immunofluorescence | MCM2 / H3K9me2 / CD63 |
|
26637368 | |
| 体内研究(In Vivo) | ||
| 体内研究活性 | 在小鼠中，Akti-1/2 (50 mg/kg, i.p.)抑制肺中基底和IGF-刺激的Akt1和 Akt2磷酸化作用。[1] |
|
|---|---|---|
化学信息&溶解度
| 分子量 | 551.64 | 分子式 | C34H29N7O |
| CAS号 | 612847-09-3 | SDF | Download Akti-1/2 SDF |
| Smiles | C1CN(CCC1N2C3=CC=CC=C3NC2=O)CC4=CC=C(C=C4)C5=C(N=C6C=C7C(=NC=N7)C=C6N5)C8=CC=CC=C8 | ||
| 储存条件(自收到货起) | |||
|
体外溶解度 |
DMSO : 22 mg/mL ( (39.88 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
Tags: buy Akti-1/2 | Akti-1/2 supplier | purchase Akti-1/2 | Akti-1/2 cost | Akti-1/2 manufacturer | order Akti-1/2 | Akti-1/2 distributor
